Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001
Phase 1Phase 2Fast TrackAcquisition
Fast Track Designation underscores the high unmet medical need for treatment and prevention of acute respiratory distress syndrome (ARDS)
TORONTO--(BUSINESS WIRE)-- Vasomune Therapeutics, Inc., has announced today that the US Food and Drug Administration (FDA) granted Fast Track designation for AV-001 for the prevention or treatment of moderate-to-severe ARDS in patients hospitalized with viral and/or bacterial respiratory infections. AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor which plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space.
Fast track designation represents a significant regulatory milestone and has been granted based on the potential for AV-001 to address an unmet medical need in ARDS, a global disease characterized by extremely high mortality rates, reaching up to 46% in patients with severe cases. Data from the Phase 1 study established safety, a pharmacokinetic pro to once-daily dosing and Tie2 activation demonstrating strong on-target activity. With the co-development support of AnGes Inc., AV-001 is currently in a Phase 2a clinical trial for prevention and treatment of ARDS in pneumonia and is actively recruiting.
“Vasomune is focused on the persisting unmet needs of people grappling with ARDS and other diseases driven by vascular endothelial instability,” said Dr. Brian Jahns, President and Chief Operating Officer. “Vasomune is indebted to the United States Department of Defense Congressionally Directed Medical Research Programs award #PR191212 for support to advance AV-001 to the clinic and award #PR203503 for support to research AV-001 in Phase 2a. Vasomune is also grateful to the National Research Council of Canada Industrial Research Assistance Program for providing research and development funding which supported the Phase 1 study.”
Ei Yamada, President & CEO of AnGes, said that “The FDA’s support of expedited development marks another important milestone in our endeavor to change the treatment paradigm with AV-001. We look forward to future success with the Phase 2a study, AV001-004.”
About AV-001
Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. [TYO: 4563]. AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature. AV-001 activates the nonredundant Tie2-Angiopoietin signaling axis, and through stimulation of multiple downstream pathways normalizes the vasculature by enhancing endothelial cell stability, restoring normal barrier defense, and blocking vascular leak. Vascular dysfunction contributes to the underlying disease pathophysiology in patients with bacterial and viral acute respiratory distress syndrome, sepsis, hemorrhagic shock, acute kidney injury, stroke, and vascular dementia. Importantly, in multiple pre-clinical studies AV-001 tightened endothelial cell-cell junctions and promoted endothelial cell survival, which reduced pulmonary edema, and improved lung function compared to untreated controls translating into significantly improved survival.
About Vasomune Therapeutics, Inc.
Vasomune Therapeutics, Inc. is a private clinical-stage biopharmaceutical company developing the next generation of medicines to harness the body’s ability to defend against illness. Founded in 2014, Vasomune has focused on vascular normalization strategies, and has progressed the lead candidate AV-001 from bench to bedside. Vascular dysfunction is associated with the pathology of several disease states, including bacterial and viral acute respiratory distress syndrome, sepsis, hemorrhagic shock, acute kidney injury, stroke, and vascular dementia. Vasomune’s corporate headquarters and laboratories are located in Toronto, Canada with US offices in Raleigh, NC. For more information about the company please visit .
About AnGes, Inc.
AnGes, Inc., a biopharmaceutical company founded in December 1999, focuses on the development of gene-based medicines. In March 2019, AnGes obtained conditional and time-limited approval for its lead product, Collategene® (Hepatocyte Growth Factor; HGF—plasmid gene therapy), for the treatment of lower limb ischemic ulcers. In September 2019, AnGes commenced commercialization in Japan of Collategene®, the world’s first marketed drug using plasmid DNA. AnGes is currently working on the development of a Tie2 tyrosine kinase receptor agonist (AV-001) for COVID-19, viral and bacterial-associated pneumonia and an NF-κB decoy oligonucleotide for chronic discogenic lumbar back pain. Furthermore, AnGes acquired EmendoBio in December 2020 to expand its capabilities in genome-editing technologies. For more information, visit .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.